J. Goldman & Co LP Makes New Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)

J. Goldman & Co LP bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 26,335 shares of the company’s stock, valued at approximately $1,152,000.

A number of other large investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in Revolution Medicines by 54.5% in the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company’s stock worth $414,777,000 after purchasing an additional 3,346,755 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in Revolution Medicines in the fourth quarter worth about $994,000. Ensign Peak Advisors Inc raised its holdings in Revolution Medicines by 667.1% in the fourth quarter. Ensign Peak Advisors Inc now owns 305,172 shares of the company’s stock worth $13,348,000 after purchasing an additional 265,389 shares in the last quarter. Farallon Capital Management LLC raised its holdings in Revolution Medicines by 17.1% in the fourth quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company’s stock worth $579,498,000 after purchasing an additional 1,931,000 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in Revolution Medicines by 57.8% in the fourth quarter. Deutsche Bank AG now owns 177,383 shares of the company’s stock worth $7,759,000 after purchasing an additional 64,997 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Revolution Medicines news, insider Mark A. Goldsmith sold 11,738 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $458,251.52. Following the sale, the insider now owns 441,564 shares in the company, valued at approximately $17,238,658.56. This represents a 2.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the transaction, the chief operating officer now owns 153,533 shares in the company, valued at $5,993,928.32. This trade represents a 1.95% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,660 shares of company stock worth $650,406. Corporate insiders own 8.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on RVMD. Stifel Nicolaus cut their price objective on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Oppenheimer upped their price objective on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday. Guggenheim cut their price objective on shares of Revolution Medicines from $87.00 to $80.00 and set a “buy” rating on the stock in a report on Thursday. HC Wainwright upped their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a report on Monday, March 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $57.00 price objective on shares of Revolution Medicines in a report on Thursday. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $67.17.

Revolution Medicines Trading Down 3.2%

Shares of NASDAQ:RVMD opened at $40.58 on Monday. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The company’s 50 day moving average is $37.36 and its 200 day moving average is $43.39. The company has a market cap of $7.56 billion, a PE ratio of -11.30 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period last year, the firm posted ($0.70) earnings per share. Equities research analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.